Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: A phase 1-2 study: Research paper

British Journal of Haematology

Volumn 150, Issue 1, 2010, Pages 58-71

  Coiffier, Bertrand ^a   Losic, Nedjad ^b   Rønn, Birgitte Biilmann ^c   Lepretre, Stéphane ^d   Pedersen, Lars Møller ^e   Gadeberg, Ole ^f   Frederiksen, Henrik ^g   Van Oers, Marinus H J ^h   Wooldridge, James ⁱ   Kloczko, Janusz ^j   Holowiecki, Jerzy ^k   Hellmann, Andrzej ^l   Walewski, Jan ^m   Robak, Tadeusz ⁿ   Petersen, Jørgen ^c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b H LUNDBECK A S   (Denmark)

^c Genmab   (Denmark)

^d CENTRE HENRI BECQUEREL   (France)

^e ROSKILDE HOSPITAL   (Denmark)

^f LILLEBAELT HOSPITAL   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ UNIVERSITY OF IOWA   (United States)

^j MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^k Uniwersytetu Medycznego w   (Poland)

^l MEDICAL UNIVERSITY OF GDANSK   (Poland)

^m INSTITUTE OF ONCOLOGY   (Poland)

ⁿ MEDICAL UNIVERSITY OF LODZ   (Poland)

more..

Author keywords

Chronic lymphocytic leukaemia; Intravenous infusion; Monoclonal antibody; Ofatumumab; PK PD

Indexed keywords

OFATUMUMAB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; INFECTION; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY PERIOD; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

EID: 77953517111     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08193.x     Document Type: Article

References (23)

1. Berinstein, N.L., Grillo-López, A.J., White, C.A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P. Shen, D. (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 9, 995 1001.
2. Bleeker, W.K., Munk, M.E., Mackus, W.J.M., van den Brakel, J.H.N., Pluyter, M., Glennie, M.J., Van de Winkel, J.G.J. Parren, P.W.H.I. (2008) Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. British Journal of Haematology, 140, 301 312.
3. Cheson, B.D., Bennett, J.M., Rai, K.R., Grever, M.R., Kay, N.E., Schiffer, C.A., Oken, M.M., Keating, M.J., Boldt, D.H., Kemoin, S.J. Foon, K.A. (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. American Journal of Hematology, 29, 152 163.
4. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brian, S. Rai, K.R. (1996) National Cancer Institute-Sponsored Working Group Guidelines For Chronic Lymphocytic Leukemia - Revised Guidelines For Diagnosis and Treatment. Blood, 87, 4990 4997.
5. Chiorazzi, N., Rai, K.R. Ferrarini, M. (2005) Chronic lymphocytic leukemia. New England Journal of Medicine, 352, 804 815.
6. Coiffier, B., Lepretre, S., Pedersen, L.M., Gadeberg, O., Frederiksen, H., Van Oers, M.H.J., Wooldridge, J., Kloczko, J., Holowieki, J., Hellmann, A., Walewski, J., Flensburg, M., Petersen, J. Robak, T. (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed of refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood, 111, 1094 1100.
7. Daydé, D., Ternant, D., Ohresser, M., Lerondel, S., Pesnel, S., Watier, H., Le Pape, A., Bardos, P., Paintaud, G. Cartron, G. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic- pharmakodynamic modeling using a syngenic bioluminescent murine model expressing human CD20. Blood, 113, 3765 3772.
8. Du Bois, D. Du Bois, E.F. (1916) Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known. Archives of Internal Medicine, 17, 863 871.
9. Hagenbeek, A., Gadeberg, O., Johnson, P., Pedersen, L.M., Walewski, J., Hellmann, A., Link, B.K., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., Kneba, M., Engert, A., Sonneveld, P., Flensburg, M., Petersen, J., Losic, N. Radford, J. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 111, 5486 5495.
10. Huhn, D., von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., Knauf, W., Riedel, U., Hinke, A., Srock, S., Peschel, C. Emmerich, B. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 98, 1326 1331.
11. Igarashi, T., Kobayashi, Y., Ogure, M., Kinoshita, T., Ohtsu, T., Sasaki, Y., Morishima, Y., Murate, T., Kasai, M., Uike, N., Taniwaki, M., Kano, Y., Ohnishi, K., Matsuno, Y., Nakamura, S., Mori, S., Ohashi, Y. Tobinai, K. (2002) Factors affecting toxocity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Annals of Oncology, 13, 928 943.
12. Itälä, M., Geisler, C.H., Kimby, E., Juvonen, E., Tjonnfjord, G., Karlsson, K. Remes, K. (2002) Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. European Journal of Haematology, 69, 129 134.
13. Kuester, K. Kloft, C. (2006) Pharmacokinetics of monoclonal antibodies. In : Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development (ed. by B. Meibohm pp. 45 91. Wiley-VCH
14. Leyland-Jones, B., Arnold, A., Gelmon, K., Verma, S., Ayoub, J.P., Seidman, A., Dias, R., Howell, J. Rakhit, A. (2001) Pharmacologic insights into the future of trastuzumab. Annals of Oncology, 12 (Suppl. 1 S43 S47.
15. Mangel, J., Buckstein, R., Imrie, K., Spaner, D., Franssen, E., Pavlin, P., Boudreau, A., Pennell, N., Combs, D. Berinstein, N.L. (2003) Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vitro purge' and consolidative immunotherapy following autologous stem cell transplantation. Annals of Oncology, 14, 758 765.
16. Mould, D.R., Davis, C.B., Minthorn, E.A., Kwok, D.C., Elliot, M.J., Luggen, M.E. Totoritis, M.C. (1999) A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 66, 246 257.
17. ®) in patients with chronic lymphocytic leukaemia and its link to treatment response. British Journal of Clinical Pharmacology, 64, 278 291.
18. O'Brien, S.M., Kantarjian, H., Thomas, D.A., Giles, F.J., Freireich, E.J., Cortes, J., Lemer, S. Keating, M.J. (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 2165 2170. (Pubitemid 32366970)
19. Plosker, G.L. Figgitt, D.P. (2003) Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 63, 803 843.
20. Teeling, J.L., French, R.R., Cragg, M.S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P.W.H.I., Hack, C.E., Dechant, M., Valerius, T., van de Winkel, J.G.J. Glennie, M.J. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood, 104, 1793 1800.
21. Teeling, J.L., Marcus, W.J.M., Wiegman, L.J.J.M., van den Brakel, J.H.N., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W.H.I., Glennie, M.J. van de Winkel, J.G.J. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of Immunology, 177, 362 371.
22. Tobinai, K., Kobayashi, Y., Narabayashi, M., Ogura, M., Kagami, Y., Morishima, Y., Ohtsu, T., Igarashi, T., Sasaki, Y., Kinoshita, T., Murate, T. members of the IDEC-C2B8 study group. (1998) Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in relapsed B-cell lymphoma. Annals of Oncology, 9, 527 543.
23. Tobinai, K., Igarashi, T., Itoh, K., Kobayashi, Y., Taniwaki, M., Ogura, M., Kinoshita, T., Hotta, T., Aikawi, K., Tsushita, K., Hiraoka, A., Matsuno, Y., Mori, S. Ohashi, Y. (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Annals of Oncology, 15, 821 830.